IRWD - Ironwood Pharmaceuticals Non-GAAP EPS of $0.27 beats by $0.01 revenue of $107.2M misses by $1.02M guidance in-line
- Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q4 Non-GAAP EPS of $0.27 beats by $0.01 .
- Revenue of $107.2M (-8.5% Y/Y) misses by $1.02M .
- For FY23, expected revenue is $420 to $435 million, vs. consensus of $426.65M.
- U.S. LINZESS Net Sales Growth of 3% to 5%, and Adjusted EBITDA of >$250 million.
For further details see:
Ironwood Pharmaceuticals Non-GAAP EPS of $0.27 beats by $0.01, revenue of $107.2M misses by $1.02M, guidance in-line